Abbott Laboratories

ABT · Healthcare · · USD

108.33 USD

0.00 (-0.42%)

● Updated 2026-09-07 21:04 Saudi Time ↻ Refresh

Short-term Mid-term Long-term

Fahodi Score HOLD Mid-term (Position)

/ 100

Technical 50

Trend & RS 65

Momentum 62

Fundamental 83

Macro 64

Liquidity 50

Component	Score	Weight
Technical	50.0	20%
Trend & RS	65.4	30%
Momentum	62.0	15%
Fundamental	83.3	10%
Macro	64.4	20%
Liquidity	49.8	5%

Trade Setup

Entry	108.33
Stop Loss	102.71 (5.2%)
Target 1 (1:1)	113.95 (+5.2%)
Target 2 (2:1)	119.57 (+10.4%)

ATR(14)	2.81 (2.6%)
Risk per Share	5.62
Reward:Risk	2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor	Score	Z
Value	47.1	-0.12
Momentum	62.0	+0.48
Quality	36.5	-0.54
Composite	48.5

Quality Scores

Piotroski F-Score 6 /9 — Average

✓ ✓ ✗ ✗ ✓ ✗ ✓ ✓ ✓

1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover

Altman Z-Score 5.29 — Safe Zone

Distress <1.81Grey 1.81–2.99>2.99 Safe

Valuation vs Peers Overvalued

Metric	Stock	Sector	vs Peers
P/E Ratio	35.1	22.0	+59% above
P/B Ratio	3.7	4.0	Inline
Dividend Yield	2.3%	1.5%	Above avg

Comparing against Healthcare median multiples.

Trading at a premium to sector peers — verify growth justifies premium.

Intrinsic Value (DCF) Significantly Overvalued

Intrinsic Value

60.47

Market Price

108.33

Upside

-44.2%

Margin of Safety	-79.2%
Stage 1 PV (5yr FCF)	23,860,555,917
Terminal Value PV	80,772,033,539
Total Enterprise Value	104,632,589,456

Assumptions

Base FCF	4,277,507,508
Growth Rate (5yr)	13.0%
Terminal Growth	2.5%
Discount Rate (WACC)	9.0%

2-stage DCF: 5yr projected FCF + Gordon Growth terminal value. Estimates only — adjust growth and WACC for your own assumptions.

Position Sizing — Kelly Criterion

4.5%

Recommended Size

41.14%

Full Kelly

20.57%

Half Kelly

5.0%

Max Cap (Moderate)

Kelly inputs derived from quant score 63/100. Estimated win rate 59%, avg win 8.8%, avg loss 3.7%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

BEAR Regime: BEAR (20% confidence) — position size reduced 10%

Signal Summary BUY

Bullish Signals

Bearish Signals

47.4

RSI(14)

1.3872

MACD

Relative Strength (RS) WEAK RS

/ 99

RS Rating

O'Neil filter: <80

RS vs SPY	↑ RISING (+15.1% vs SPY 3M)
RS vs Sector	OUTPERFORMING (Healthcare)
RS New High	No (9d since high)
Sector Outperformance	+12.0% (3M)

RS Line — stock / SPY (90 bars)

← older newer →

RS vs SPY 50-day SMA of RS

WEAK RS: Underperformer — the stock is lagging the market. Avoid until RS trend reverses upward.

Technical Indicators

Indicator	Value	Signal
Rsi	47.4	NEUTRAL
Macd	1.3872	BEARISH
Ma Cross	104.21 / 105.22	DEATH CROSS
Trend Short		ABOVE SMA50
Trend Long		ABOVE SMA200
Bollinger		MIDDLE
Volume	0.94x	NORMAL

Key Levels

Level	Price
52-Week High	137.49
Bollinger Upper	117.24
SMA(200)	105.22
SMA(50)	104.21
SMA(20)	111.89
Current Price	108.33
Bollinger Lower	106.55
52-Week Low	81.97
ATR(14)	2.81

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

MARKUP Confidence

100%

Acc: 0.0 | Dist: 0.0 | Markup: 2.0 | Markdown: 0.0

Volume Spread Analysis (last 5 bars)

Date	Signal	Vol	Description
2026-08-31	Normal	1.43x	Normal bar — no special VSA pattern
2026-09-01	Normal	0.97x	Normal bar — no special VSA pattern
2026-09-02	Normal	1.13x	Normal bar — no special VSA pattern
2026-09-03	Normal	0.71x	Normal bar — no special VSA pattern
2026-09-04	Normal	0.94x	Normal bar — no special VSA pattern

Ichimoku Cloud NEUTRAL

Line	Value	Status
Tenkan-sen (9)	112.04	Above Kijun
Kijun-sen (26)	110.12	Base line
Senkou A	111.08	Leading span A
Senkou B	102.49	Leading span B
Cloud	102.49 – 111.08	Bullish (Green)
Price vs Cloud	108.33	Inside Cloud
Chikou Span	105.70	Bullish
Alignment Score	3/4	NEUTRAL